A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA

Monomeric IgA has been proposed as an alternative antibody format for cancer therapy. Here, we present our studies on the production, purification and functional evaluation of anti-HER2 IgA antibodies as anti-cancer agents in comparison to the anti-HER2 IgG1 trastuzumab. MALDI-TOF MS analysis showed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:MAbs
Autori principali: Rouwendal, Gerard JA, van der Lee, Miranda M, Meyer, Saskia, Reiding, Karli R, Schouten, Jan, de Roo, Guy, Egging, David F, Leusen, Jeanette HW, Boross, Peter, Wuhrer, Manfred, Verheijden, Gijs F, Dokter, Wim H, Timmers, Marco, Ubink, Ruud
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2015
Soggetti:
Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966520/
https://ncbi.nlm.nih.gov/pubmed/26440530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1102812
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi